OrbusNeich to validate bioengineered stent
This article was originally published in Clinica
Executive Summary
Just weeks after announcing it had CE-marked for sale in Europe the first bioengineered stent, Genous, Hong Kong firm OrbusNeich is pressing on with its clinical trial programme to substantiate the product's efficacy. The company has begun a global internet-based registry called e-HEALING, which will assess outcomes of 5,000 patients enrolled at over 100 centres; the device is currently only available through the registry. The registry is sufficiently large to generate the data needed to quantify the technology's safety profile, said the company. The company has also completed the design phase of an upcoming randomised trial, called HEALING III, which will involve angiographic follow up to compare Genous stents with bare metal stents both in conjunction with statin therapy. HEALING III is scheduled to start later this year or in early 2006.
You may also be interested in...
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
ATAI Raises $125m Series C To Expand The Boundaries In Mental Health
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: